CURRENT ISSUE
February, 2021

No. 106 (2)

2019 Impact Factor: 7.116
ARTICLES IN THREE SENTENCES
Article

Signal-transducing adaptor protein-2 delays recovery of B lineage lymphocytes during hematopoietic stress

Signal-transducing adaptor protein-2 (STAP-2) functions as an adaptor of signaling or transcription factors. It has roles in inflammatory reactions, cell survival, migration and cell adhesion in macrophages, T cells or mast cells. This study investigated STAP-2-mediated regulation of stress hematopoiesis using genetically modified mice and concluded that it modulates formation of B lymphocytes in demand conditions. Further study of this adapter protein could reveal ways to speed recovery of humoral immunity following chemotherapy or transplantation.

Michiko Ichii et al.

Article

Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

Selective blockade of plasminogen activator inhibitor-1 (PAI-1) enhanced the susceptibility of chronic myeloid leukemia stem cells to tyrosine kinase inhibition. PAI-1 inhibitor treatment augmented membrane-type matrix metalloprotease-1-dependent motility of leukemic stem cells. These findings provide a rationale for a novel tactic for treating patients with chronic myeloid leukemia, based on the blockade of PAI-1 activity.

Takashi Yahata et al.

Article

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas

The levels of cell-free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. After evaluating the cerebrospinal fluid (CSF) and plasma from 19 patients (6 with restricted central nervous system [CNS] lymphomas, 1 with systemic and CNS lymphoma, and 12 with systemic lymphomas), the authors concluded that CSF ctDNA can detect CNS lesions better than plasma ctDNA and flow cytometry for tumor cells in CSF. In addition, CSF ctDNA predicts CNS relapse in CNS and systemic lymphomas. This technology can be exploited as a 'liquid biopsy' of CNS lymphomas.

Sabela Bobillo et al.

Letter

Down syndrome-related transient abnormal myelopoiesis is attributed to a specific erythro-megakaryocytic subpopulation with GATA1 mutation

Down syndrome-related transient abnormal myelopoiesis (TAM) is a temporary preleukemic state in which there is marked elevation of blast cells at birth. This study identified the disease-responsible progenitors and impact of GATA1 mutations on these cells by dissecting the differentiation steps of pluripotent stem cell-based hematopoiesis. This model should provide novel insights into the pathogenesis, prediction, and treatment of not only TAM, but also acute megakaryocytic leukemia in Down syndrome.

Yoko Nishinaka-Arai et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA